The Patent Finder

Caerus Therapeutics, Inc.

Also on record
Records under this name other than patents Caerus Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 6 of 6 · Back to Caerus Therapeutics, Inc.

PatentTitleStatus Expires Confidence
US 11,623,953Antibody Constructs and Methods of Treating Cancer
Formerly held
In force
 · High confidence
In forceHigh confidence
US 6,376,654Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
Term ended
Term ended Aug 13, 2019 · From the USPTO record
Term endedTerm ended Aug 13, 2019From the USPTO record
US 7,226,750Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
Lapsed on the fee record
Ended Jun 5, 2019 · From the USPTO record
Lapsed on the fee recordEnded Jun 5, 2019From the USPTO record
US 7,691,376Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
Lapsed on the fee record
Ended Apr 6, 2018 · From the USPTO record
Lapsed on the fee recordEnded Apr 6, 2018From the USPTO record
US 6,986,891Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
Lapsed on the fee record
Ended Jan 17, 2018 · From the USPTO record
Lapsed on the fee recordEnded Jan 17, 2018From the USPTO record
US 7,498,129Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
Lapsed on the fee record
Ended Mar 3, 2017 · From the USPTO record
Lapsed on the fee recordEnded Mar 3, 2017From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited